Clinical trial results by Recover Right revealed a survival rate of 73 percent in the total patient population. Recover Right was an FDA-approved, prospective, multicenter, single arm study designed to evaluate the safety and probable benefit of the Impella RP in patients with right ventricular failure (RVF) refractory to medical treatment and deemed to require hemodynamic support.

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a higher quality of life than a best-in-class, permanent, metallic drug-eluting stent.

St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. 

More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptoms[1] of peripheral arterial disease (PAD).

October 8, 2014 — Miracor Medical Systems announced that results from the prospective multicenter safety and feasibility study, ‘Prepare RAMSES,’ were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference last month in Washington, D.C., by co-investigator Tim P. van de Hoef, M.D., fellow of Jan Piek, M.D., Ph.D., principal investigator for the trial at Academic Medical Center, University of Amsterdam.

Claret Medical announced the first patient has been successfully treated in its SENTINEL trial, a multicenter pivotal trial of the Sentinel cerebral protection system (CPS). The landmark trial is the first prospective, randomized, controlled, blinded trial in the United States to evaluate the role of cerebral protection during transcatheter aortic valve replacement (TAVR).

Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and feasibility of the company's Fortitude Sirolimus-Eluting Bioresorbable Scaffold in patients with symptomatic coronary artery disease.

Medtronic Inc. announced the U.S. launch of the SEEQ Mobile Cardiac Telemetry (MCT) System, an external, wire-free, adhesive heart monitor that can be worn for up to 30 days to help detect and diagnose the cause of irregular heartbeats in patients. Medtronic completed the acquisition of U.S.-based Corventis Inc., which developed the technology, in June 2014.

Occlutech  announced that it has obtained a European CE mark approval for its dedicated Paravalvular Leak Closure Device (PLD).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now